Cargando…

Impact of a physician-led exercise programme on quality of life, muscle mass and clinical response in inflammatory bowel disease patients during induction with disease-modifying therapy: a study protocol

INTRODUCTION: Biologic and small-molecule therapies have revolutionised the treatment of moderate-to-severe inflammatory bowel disease (IBD). A significant proportion of patients experience early or delayed treatment failure. Patients with IBD with greater visceral obesity are less likely to respond...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mc Gettigan, Neasa, Hanley, Marion, Skelly, Fiona, Dowling, Jennifer, Dunne, Ruth, Morrin, Martina M, McCaffrey, Noel, O'Toole, Aoibhlinn, Boland, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441810/ http://dx.doi.org/10.1136/bmjgast-2022-000959

Ejemplares similares

Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772)
por: Sheridan, Juliette, et al.
Publicado: (2018)

“Role of exercise in preventing and restoring gut dysbiosis in patients with inflammatory bowel disease”: A letter to the editor
por: Mc Gettigan, Neasa, et al.
Publicado: (2022)

Body image dissatisfaction in patients with inflammatory bowel disease: a systematic review
por: Beese, Sophie Elizabeth, et al.
Publicado: (2019)

Perianal fistulizing Crohn's disease and overall risk of cancer: No red flag
por: McLellan, Paul, et al.
Publicado: (2023)

Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience
por: Barreiro‐de Acosta, Manuel, et al.
Publicado: (2021)

Genital warts and inflammatory bowel diseases: Danish real‐world evidence to assess patient‐relevant outcomes
por: McLellan, Paul, et al.
Publicado: (2022)

Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
por: Cayatte, Corinne, et al.
Publicado: (2012)

A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Crohn’s disease therapeutic dietary intervention (CD-TDI): study protocol for a randomised controlled trial
por: Raman, Maitreyi, et al.
Publicado: (2022)

Identifying and understanding disease burden in patients with inflammatory bowel disease
por: Christensen, Katrine Risager, et al.
Publicado: (2022)

Creeping fat formation and interaction with intestinal disease in Crohn's disease
por: Yin, Yi, et al.
Publicado: (2022)

Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease
por: Schwerd, Tobias, et al.
Publicado: (2017)

Smoking and colorectal neoplasia in patients with inflammatory bowel disease: Dose‐effect relationship
por: Wijnands, Anouk M., et al.
Publicado: (2023)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Developing a core outcome set for fistulising perianal Crohn’s disease
por: Sahnan, Kapil, et al.
Publicado: (2019)

Faster and less invasive tools to identify patients with ileal colonization by adherent‐invasive E. coli in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

High incidence of glucocorticoid-induced hyperglycaemia in inflammatory bowel disease: metabolic and clinical predictors identified by machine learning
por: McDonnell, Martin, et al.
Publicado: (2020)

A microbial signature for Crohn's disease
por: Pascal, Victoria, et al.
Publicado: (2017)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Bacterial protein signals are associated with Crohn’s disease
por: Juste, Catherine, et al.
Publicado: (2014)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Treat‐to‐target and sequencing therapies in Crohn's disease
por: Garcia, Nicole M., et al.
Publicado: (2022)

Changing paradigms in management of inflammatory bowel disease
por: Mao, Ren, et al.
Publicado: (2022)

Environmental risk factors for inflammatory bowel disease
por: Singh, Noreen, et al.
Publicado: (2022)

New endoscopic tools in inflammatory bowel disease
por: Nardone, Olga Maria, et al.
Publicado: (2022)

Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance
por: Aschenbrenner, Dominik, et al.
Publicado: (2021)

Effectiveness of disease-specific cognitive–behavioural therapy on depression, anxiety, quality of life and the clinical course of disease in adolescents with inflammatory bowel disease: study protocol of a multicentre randomised controlled trial (HAPPY-IBD)
por: van den Brink, Gertrude, et al.
Publicado: (2016)

Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study
por: Murthy, Sanjay K, et al.
Publicado: (2020)

Cytomegalovirus colitis in inflammatory bowel disease and after haematopoietic stem cell transplantation: diagnostic accuracy, predictors, risk factors and disease outcome
por: Mavropoulou, Eirini, et al.
Publicado: (2019)

Elevated ectodomain of type 23 collagen is a novel biomarker of the intestinal epithelium to monitor disease activity in ulcerative colitis and Crohn's disease
por: Manon‐Jensen, T., et al.
Publicado: (2021)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Inability to walk: a rare presentation of Crohn’s disease
por: Hoekstra, Elmer, et al.
Publicado: (2020)

Ultrasonography in inflammatory bowel disease – So far we are?
por: Christian, Maaser, et al.
Publicado: (2022)

Menetrier’s disease exacerbating ulcerative colitis and relieved by gastrectomy
por: Kayes, Tahrima, et al.
Publicado: (2021)

Landscape of new drugs and targets in inflammatory bowel disease
por: Vieujean, Sophie, et al.
Publicado: (2022)

Is hypertension an extra‐intestinal manifestation of inflammatory bowel disease?
por: Burisch, Johan
Publicado: (2023)

Variables associated with progression of moderate-to-severe Crohn’s disease
por: Sacramento, Carolina da Silva Beda, et al.
Publicado: (2022)

Avoiding food avoidance in patients with inflammatory bowel disease
por: Godny, Lihi, et al.
Publicado: (2023)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4ksj557v0r2jge6lr6igbpub3i